Innate Pharma
Background
- Founded in ’99 as 1st mover in innate immunity pharmacology.
- Via industry contacts Gilde was informed about the 2nd round of financing.
- Gilde’s good relationship with the syndicate enabled to secure a strong position in the oversubscribed financing round.
Gilde Role Pre-investment
- Gilde primarily focused its due diligence on technology and commercial potential.
- The outcome of the due diligence supported the unique technology and IP base and the large medical need and commercial potential of this new class of drugs.
- Also the strength of management team, the quality of preliminary experimental data and the quality of the investor syndicate contributed to our decision to invest.
Gilde Role Post-investment
- Gilde introduced a former Pharma executive to represent the Series C investors on the Board and took a position of board observer.
- Gilde supported the company in recruitment, business development and corporate development issues.
- Gilde invited institutional investors who made significant investments in the IPO of the company.
Post Investment Developments
- Advanced its product pipeline from preclinical into clinical development.
- Validated the technology by a large collaboration deal with Novo Nordisk.
- Successful in-licensing of a high quality product platform from a major Pharma company.
- Raised EUR 50 million in multiple equity financings from top tier investors and successfully raised EUR 33.7 million in a 2.5x oversubscribed, premium priced IPO on the Euronext Exchange in Paris end of 2006.
